Company profile INBX

Inhibrx Inc
development of antibodies
Quarter analysis & expected interestLast update: February 09 2024 13:30:57.

After 39 days of this quarter the interest is at 145.0. Based on that we can calculate that during remaining 52 days it will total up to 338.0.
Inhibrx expected interest is significantly higher compared to previous quarter (+436.5%) and same quarter last year (+344.7%).

YearQ1Q2Q3Q4
201918
49
172.2% QoQ
82
67.3% QoQ
17
-79.3% QoQ
2020 25
38.9% YoY 47.1% QoQ
47
-4.1% YoY 88.0% QoQ
170
107.3% YoY 261.7% QoQ
108
535.3% YoY -36.5% QoQ
2021 54
116.0% YoY -50.0% QoQ
90
91.5% YoY 66.7% QoQ
80
-52.9% YoY -11.1% QoQ
125
15.7% YoY 56.2% QoQ
2022 57
5.6% YoY -54.4% QoQ
89
-1.1% YoY 56.1% QoQ
110
37.5% YoY 23.6% QoQ
55
-56.0% YoY -50.0% QoQ
2023 76
33.3% YoY 38.2% QoQ
70
-21.3% YoY -7.9% QoQ
55
-50.0% YoY -21.4% QoQ
63
14.5% YoY 14.5% QoQ
2024 145
90.8% YoY 130.2% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Inhibrx search interestLast update: February 09 2024 13:30:57.
Correlation coefficient between keyword and revenue is 0.81
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 13:30:59.

The average 5 years interest of Inhibrx was 6.07 per week.
The last year interest of Inhibrx compared to the last 5 years has changed by 15.65%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 105.26%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Inhibrx Inhibrx biopharmaceutical to provide analysis

Correlation between past revenue and Inhibrx Inhibrx biopharmaceutical search interest

There is not enough data for Inhibrx Inhibrx biopharmaceutical to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Inhibrx Inhibrx biopharmaceutical to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Inhibrx pipeline to provide analysis

Correlation between past revenue and Inhibrx pipeline search interest

There is not enough data for Inhibrx pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Inhibrx pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for INBRX-109 to provide analysis

Correlation between past revenue and INBRX-109 search interest

There is not enough data for INBRX-109 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for INBRX-109 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for INBRX-105 to provide analysis

Correlation between past revenue and INBRX-105 search interest

There is not enough data for INBRX-105 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for INBRX-105 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for INBRX-101 to provide analysis

Correlation between past revenue and INBRX-101 search interest

There is not enough data for INBRX-101 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for INBRX-101 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for INBRX-106 to provide analysis

Correlation between past revenue and INBRX-106 search interest

There is not enough data for INBRX-106 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for INBRX-106 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for tetravalent agonist of death receptor 5 to provide analysis

Correlation between past revenue and tetravalent agonist of death receptor 5 search interest

There is not enough data for tetravalent agonist of death receptor 5 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for tetravalent agonist of death receptor 5 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for conditional agonist of programmed death-ligand 1 to provide analysis

Correlation between past revenue and conditional agonist of programmed death-ligand 1 search interest

There is not enough data for conditional agonist of programmed death-ligand 1 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for conditional agonist of programmed death-ligand 1 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for alpha-1 antitrypsin (AAT)-Fc fusion protein to provide analysis

Correlation between past revenue and alpha-1 antitrypsin (AAT)-Fc fusion protein search interest

There is not enough data for alpha-1 antitrypsin (AAT)-Fc fusion protein to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for alpha-1 antitrypsin (AAT)-Fc fusion protein to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for hexavalent agonist of OX40. to provide analysis

Correlation between past revenue and hexavalent agonist of OX40. search interest

There is not enough data for hexavalent agonist of OX40. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for hexavalent agonist of OX40. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for INBX
Earnings date: 2024-03-06 After close
Company name: Inhibrx Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T16:02:00-04:00

PR Newswire
Inhibrx Reports First Quarter 2026 Financial Results

2026-05-11T08:00:00-04:00

PR Newswire
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

2026-05-08T16:00:00-04:00

PR Newswire
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

2026-04-21T16:05:00-04:00

PR Newswire
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

2026-04-20T17:03:00-04:00

PR Newswire
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

2026-04-08T13:25:28Z

Analyst Upgrades
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

2026-04-08T09:25:25Z

Analyst Upgrades
Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150

2026-03-19T16:00:00-04:00

PR Newswire
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

2026-03-02T16:00:00-05:00

PR Newswire
Inhibrx Announces Participation in Upcoming Scientific Conference

2025-12-16T17:00:00-05:00

PR Newswire
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

2025-11-14T06:00:00-05:00

PR Newswire
Inhibrx Reports Third Quarter 2025 Financial Results

2025-11-04T16:01:00-05:00

PR Newswire
Inhibrx Announces Participation in Upcoming Scientific Conferences

2025-10-23T16:05:00-04:00

PR Newswire
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

2025-10-22T16:01:00-04:00

PR Newswire
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

2025-10-17T18:13:44-04:00

SEC
SCHEDULE 13G/A Form - [Amend] Statement of Beneficial Ownership by Certain Investors - Inhibrx Biosciences, Inc. (0002007919) (Subject)